Preliminary results from phase 2 of CC-92480-MM-001: Mezigdomide plus dexamethasone in relapsed/refractory multiple myeloma (RRMM)

被引：0

作者：

Popat, Rakesh ^{[1
]}

Richardson, Paul G. ^{[2
]}

Trudel, Suzanne ^{[3
]}

Quach, Hang ^{[4
]}

Lonial, Sagar ^{[5
]}

Orlowski, Robert Z. ^{[6
]}

Kim, Kihyun ^{[7
]}

Mateos, Maria-Victoria ^{[8
]}

Pawlyn, Charlotte ^{[9
,10
]}

Ramasamy, Karthik ^{[11
]}

Martinez-Lopez, Joaquin ^{[12
]}

Casas-Aviles, Ignacio ^{[13
]}

Spirli, Alessia ^{[14
]}

Gong, Jing ^{[15
]}

Amatangelo, Michael ^{[15
]}

Katz, Jessica ^{[15
]}

Maciag, Paulo ^{[15
]}

Peluso, Teresa ^{[14
]}

Bahlis, Nizar J. ^{[16
]}

机构：

[1] Univ Coll London Hosp NHS Fdn Trust, NIHR UCLH Clin Res Facil, London, England

[2] Dana Farber Canc Inst, Boston, MA USA

[3] Univ Toronto, Div Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada

[4] Univ Melbourne, St Vincents Hosp Melbourne, Melbourne, Australia

[5] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

[7] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea

[8] Univ Hosp Salamanca, IBSAL, Salamanca, Spain

[9] Royal Marsden NHS Fdn, London, England

[10] Inst Canc Res, London, England

[11] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Oxford, England

[12] Univ Complutense Madrid, Hosp Octubre, Hosp 12 Octubre, Dept Hematol,CIBERONC, Madrid, Spain

[13] Hosp San Pedro Alcantara, Caceres, Spain

[14] Celgene Int Sarl Bristol Myers Squibb Co, Boudry, Switzerland

[15] Bristol Myers Squibb, Princeton, NJ USA

[16] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH23-PO15

引用

页码：66 / 67

页数：2

共 50 条

[21] Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)
Richardson, Paul G.
Mikhael, Joseph
Usmani, Saad Z.
Raje, Noopur
Bensinger, William
Kanagavel, Dheepak
Gao, Lei
Ziti-Ljajic, Samira
Anderson, Kenneth C.
BLOOD, 2017, 130
[22] Preliminary Results From a Phase Ib Study of Isatuximab in Combination with Pomalidomide (Pom) and Dexamethasone (Dex) in Relapsed and Refractory Multiple Myeloma (RRMM)
Richardson, Paul
Mikhael, Joseph
Usmani, Saad
Raje, Napoor
Bensinger, William
Campana, Frank
Gao, Lei
Dubin, Franck
Wack, Claudine
Anderson, Kenneth C.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E16 - E17
[23] First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Richardson, Paul G.
Vangsted, Annette J.
Ramasamy, Karthik
Trudel, Suzanne
Martinez, Joaquin
Mateos, Maria-Victoria
Rodriguez Otero, Paula
Lonial, Sagar
Popat, Rakesh
Oriol, Albert
Karanes, Chatchada
Orlowski, Robert Z.
Berdeja, Jesus G.
Wong, Lilly
Shi, Chenyang
Lamba, Manisha
Barnett, Evelyn
Pierce, Daniel W.
Pourdehnad, Michael
Bahlis, Nizar J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[24] A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Mikhael, J.
Richardson, P.
Usmani, S.
Raje, N.
Bensinger, W.
Kanagavel, D.
Gao, L.
Ziti-ljajic, S.
Anderson, K.
HAEMATOLOGICA, 2017, 102 : 168 - 168
[25] Iberdomide in combination with dexamethasone and daratumumab or bortezomib in patients with relapsed/Refractory multiple myeloma: first results from the CC-220-MM-001 study
van de Donk, Niels W. C. J.
Popat, Rakesh
Larsen, Jeremy
Minnema, Monique C.
Jagannath, Sundar
Oriol, Albert
Zonder, Jeffrey A.
Richardson, Paul G.
Rodriguez Otero, Paula
Badros, Ashraf Z.
Stadtmauer, Edward
Bringhen, Sara
Campagnaro, Erica
Siegel, David S.
Gamberi, Barbara
Gironella Mesa, Mercedes
Sonneveld, Pieter
Tuong Vi Nguyen
Di Micco, Antonia
Sorrell, April
Chen, Min
Amatangelo, Michael
Kueenburg, Elisabeth
Lonial, Sagar
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 17 - 18
[26] Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM).
Mikhael, Joseph
Richardson, Paul G.
Usmani, Saad Zafar
Raje, Noopur S.
Bensinger, William
Dubin, Franck
Liu, Qianying
Vitse, Olivier
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[27] Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 study (MM-010).
Dimopoulos, MA
Spencer, A
Attal, M
Prince, M
Harousseau, JL
Dmoszynska, A
Yu, ZU
Olesnyckyj, M
Zeldis, J
Knight, R
BLOOD, 2005, 106 (11) : 6A - 7A
[28] Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic Evaluation
Schey, Steve
Dhanasiri, Sujith
Lee, Dawn
Sternas, Lars
Yu, Xin
Zaki, Mohamed H.
Elvidge, Jamie
O'Dwyer, Michael
BLOOD, 2014, 124 (21)
[29] Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)
Jakubowiak, Andrzej
Jasielec, Jagoda
Rosenbaum, Cara A.
Cole, Craig E.
Chari, Ajai
Nam, Jennifer
Severson, Erica
Stephens, Leonor A.
McDonnell, Kathryn
Rosebeck, Shaun
Zimmerman, Todd
Karrison, Theodore
Zonder, Jeffrey
BLOOD, 2016, 128 (22)
[30] A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.
Richardson, Paul G.
Amatangelo, Michael
Berenson, James R.
Cerchione, Claudio
Dimopoulos, Meletios A.
Hansen, Charlotte Toftmann
Hwang, Soo Jeong
Koo, Phillip
Kuroda, Junya
Oriol, Albert
Orlowski, Robert Z.
Quach, Hang
Raab, Marc S.
Rocci, Alberto
Wang, Yue
White, Darrell
Yu, Brian
Zhou, Zehua
Katz, Jessica
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →